Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Formative Research

Date Submitted: Nov 19, 2025
Open Peer Review Period: Nov 20, 2025 - Jan 15, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Patient perspectives on an integrated mobile technology platform (MySafeRx) for telemedicine buprenorphine treatment: A qualitative pilot study

  • Cassandra Harding; 
  • Sarah K Moore; 
  • Grace Janzow; 
  • Amanda Sharp; 
  • Kathleen Moore; 
  • Jacob T Borodovsky; 
  • Zev Schuman-Olivier

ABSTRACT

Background:

The COVID-19 pandemic highlighted the significant impact of telemedicine-delivered Medication for Opioid Use Disorder Treatment (tMOUD). While the adoption of tMOUD provides opportunities to improve OUD treatment access and quality, more information is needed about patient perspectives on various components that can be integrated into tMOUD delivery for enhancing medication adherence.

Objective:

This qualitative study examined experiences of patients enrolled in a clinical trial that utilized the MySafeRx platform, a mobile intervention designed to integrate remote buprenorphine self-administration and motivational interviewing (MI) based recovery coaching, to increase medication adherence.

Methods:

Participants were interviewed about their experiences using the MySafeRx platform in combination with their standard MOUD treatment. Interview questions explored the utility of intervention components: text message reminders, electronic pill dispensers, MI-based mobile recovery coaching, and self-administration of medication via videoconferencing. Interviews were digitally recorded through Zoom, transcribed through Rev.com, and analyzed with ATLAS.ti.

Results:

Nine participants were interviewed. The MI-based mobile recovery coaching was reported to be the most favorable component of the platform. Participants felt it was helpful to have text reminders about upcoming coaching sessions. Video session experiences were overall positive. The electronic pill dispenser received mixed assessments: most participants felt that the supervised self-administration of medication was acceptable, while one participant reported feeling mistrusted.

Conclusions:

With the expansion of telemedicine, it is critical to understand patient perspectives of tMOUD and platform components that may increase treatment adherence. MI-based mobile recovery coaching may be particularly appealing to those receiving MOUD. These findings may be useful for the development and delivery of future tMOUD interventions to ensure acceptability and patient satisfaction alongside considerations for efficiency and resource allocation. Clinical Trial: NCT02778282, NCT04449744


 Citation

Please cite as:

Harding C, Moore SK, Janzow G, Sharp A, Moore K, Borodovsky JT, Schuman-Olivier Z

Patient perspectives on an integrated mobile technology platform (MySafeRx) for telemedicine buprenorphine treatment: A qualitative pilot study

JMIR Preprints. 19/11/2025:87681

DOI: 10.2196/preprints.87681

URL: https://preprints.jmir.org/preprint/87681

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.